Impact of Sensory, Motor and Vestibular Deficit on the Postural Stability of CMT Patients

NCT ID: NCT06425952

Last Updated: 2024-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-01

Study Completion Date

2026-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Charcot-Marie-Tooth (CMT), a therapeutically orphan neuromuscular disease affecting one in 2,500 people, represents a challenge to the medical and scientific communities. Physiotherapeutic-rehabilitative strategies play a crucial role in the management of CMT, particularly addressing balance impairment, a key disabling symptom. However, clinical studies in this field are limited. Our study aims to investigate the impact of strengh and somatosensory deficits on static and dynamic balance in CMT patients. The Investigators also aim to explore the involvement of the vestibular system and its correlation with postural instability. Furthermore, the Investigators seek to evaluate relationships between neurochemical biomarkers offering valuable insights for future targeted clinical studies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 60 patients will be recruited. To ensure adequate representation of the subgroups of interest, 10 patients with CMT1A (PMP22 gene duplication) and 10 patients with CMT2, regardless of their genotype, will be included. Additionally, three control groups, each comprising 10 subjects, will be included. The first group will consist of patients with motor symptoms, including those with hereditary motor neuropathy (HMN, 10 patients) or distal myopathy (MD, 10 patients). The second group will include patients with solely sensory symptoms, genetic neuropathies, or purely sensory acquired neuropathies such as HSN and neuropathies from anti-MAG antibodies. Finally, the third group will be composed of 10 healthy subjects. Each control subject will have comparable level of disability (motor or somatosensory), age, and gender to the enrolled CMT patients.

All participants must meet the following inclusion criteria to take part in the study:

* Age 18 years or older
* Subject has documented diagnosis of one of the following diseases (except from healthy controls):

* Hereditary sensory-motor neuropathy (CMT) confirmed by genetic analysis
* Hereditary motor neuropathy (HMN) confirmed by genetic analysis
* Hereditary sensory neuropathy (HSN) confirmed by genetic analysis
* Hereditary distal myopathy (MD) confirmed by genetic analysis
* Acquired sensory neuropathy: anti-MAG antibody neuropathy confirmed by neurophysiological, clinical and serological assessment.

The presence of any one of the following exclusion criteria will lead to the exclusion of the subject:

* Inability to maintain an upright position without assistance
* Presence of systemic, neurological (except for the neuropathies and hereditary myopathies under study), psychiatric, orthopedic or rheumatological diseases that may affect evaluation
* Mini Mental State Examination (MMSE)14 score less than 28
* History of alcohol or substance abuse
* Partecipation in intensive motor rehabilitation programs in the last three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CMT patients

patients with sensory-motor genetic neuropathy

No interventions assigned to this group

Motor patients

Patients with motor genetic neuropathy

No interventions assigned to this group

Sensory patients

Patients with sensory neuropathy

No interventions assigned to this group

Myopathic patients

Patients with distal myopathy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CMT or HMN or sensory neuropathy or distal myopathy

Exclusion Criteria

* unable to stand
* other neurological, psychiatric, or orthopedic disorders
* MMSE \<28
* alcohol abuse
* intensive rehabilitation program
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS San Raffaele

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stefano Previtali

Head Neuromuscular Repair Unit

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefano C Previtali, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Ospedale San Raffaele

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Neurology, IRCCS Ospedale San Raffaele

Milan, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stefano C Previtali, MD

Role: CONTACT

00390226433036

Benedetta Sorrenti, MD

Role: CONTACT

00390226433036

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stefano C Previtali, MD

Role: primary

00390226433036

Benedetta Sorrenti, MD

Role: backup

00390226433036

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OSRSCP-EquiCMT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.